Ditchcarbon
  • Customers
  1. Organizations
  2. Protalix BioTherapeutics
Public Profile
Pharmaceutical Preparation Manufacturing
IL
updated 5 months ago

Protalix BioTherapeutics

Company website

Protalix BioTherapeutics, a pioneering biopharmaceutical company headquartered in Israel, focuses on developing and commercialising innovative therapies for rare diseases. Founded in 2003, Protalix has made significant strides in the biotechnology sector, particularly in the production of therapeutic proteins using its proprietary plant cell-based expression system. The company’s flagship product, Elelyso, is a unique enzyme replacement therapy for Gaucher disease, showcasing Protalix's commitment to addressing unmet medical needs. With a strong emphasis on research and development, Protalix BioTherapeutics has positioned itself as a leader in the biopharmaceutical industry, achieving notable milestones in regulatory approvals and partnerships. Its operational reach extends beyond Israel, impacting patients globally with its cutting-edge therapies.

DitchCarbon Score

How does Protalix BioTherapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Protalix BioTherapeutics's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.

23%

Let us know if this data was useful to you

Protalix BioTherapeutics's reported carbon emissions

Protalix BioTherapeutics, headquartered in Israel (IL), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, Protalix BioTherapeutics has not established any significant climate commitments or initiatives aimed at reducing its carbon footprint. Without available emissions data or reduction strategies, it is unclear how the company aligns with industry standards for climate action. In the context of the biotechnology sector, companies are increasingly expected to adopt transparent climate strategies and set measurable targets to mitigate their environmental impact. However, Protalix BioTherapeutics has yet to disclose any such commitments or inherited data from a parent or related organization.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Protalix BioTherapeutics's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Protalix BioTherapeutics is in IL, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Protalix BioTherapeutics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Meridian Medical Technologies, LLC

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 13 days ago

Genzyme Corporation, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Countervail Corp.

US
Updated 13 days ago

DynPort Vaccine Company LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Actelion Pharmaceuticals Ltd

CH
•
Research and development services (73)
Updated 13 days ago

Takeda GmbH

DE
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250808.1
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy